Lausanne, Switzerland, and Tokyo, Japan – October 22, 2012 - Legacy Healthcare, a company developing
innovative products for hair and scalp disorders with a special focus on oncology supportive care, today
announced clinical results of a double-blind, placebo-controlled, long-term trial of its innovative CG210™
topical treatment in patients suffering from hair loss.
The primary endpoint of the 12-month clinical study in subjects already using finasteride 1mg as a
treatment for hair loss was the increase of mean diameter of hair. Participants received topical CG210™
or topical placebo in addition to the oral finasteride 1mg they were already taking. Finasteride, a
synthetic type-2 5a-reductase inhibitor, has been approved by the US FDA, among others, for the
treatment of male pattern baldness (MPB). As of September 27, 2012, results from 16 volunteers, who
completed a 12 month cycle, were analyzed. The mean diameter of hair of subjects receiving topical
CG210 increased 36.9% more than the mean diameter of hair of subjects receiving topical placebo
(p<0,0001). The study was conducted in Japan.
"For the study, we enrolled men who were already using finasteride for awhile and whose hair had
stopped improving,” said Dr. Akio Sato, Director of the Tokyo Memorial Clinic Hirayama, investigator of
the study. “Despite the limited number of subjects, the group using topical CG210 as an add-on to
finasteride showed a significant improvement in hair diameter compared to the group using topical
placebo as an add-on to finasteride. Improvement in hair diameter is evidence of better hair retention
and a prolonged anagen phase. For individuals who see limited improvement with finasteride, CG210
may offer a novel and very satisfactory option. Another key point is that CG210 is a botanical-based
product and no adverse events have been reported in this study."
“These are exciting times for Legacy Healthcare,” said Saad Harti, President of the company.
“Worldwide, there are at least 800,000 users of finasteride 1mg who might benefit from potentially
improved hair pattern results thanks to the combined use of CG210. The results of this study provide an
additional confirmation of the already observed clinical efficacy of our product CG210, when applied
ABOUT EXCESSIVE HAIR LOSS AND CG210™
Hair loss, e.g. induced by androgenetic alopecia, stress or chemotherapy, is characterized by excessive
apoptosis which provokes more hair to enter prematurely into the catagen phase (transition phase) and
fall. As a consequence, the anagen phase of hair (growing phase) becomes shorter.
The successive repetition of the premature onset of the catagen phase, which is caused by massive
apoptosis followed by shorter and shorter anagen phase, leads to hair miniaturization (white, invisible,
thin hair), i.e. balding.
In addition to a massive apoptosis phenomenon, excessive hair loss is also associated with scalp micro-
CG201™ has demonstrated anti hair-loss efficacy: the proportion of hair in the falling phase returned to a
level considered as normal within 44 days of product application. Its hair re-growth property was
demonstrated by an average number of new hairs of over 8,200 after 3 months of product application.
The above results were observed in a trial performed with the phototrichogram protocol on subjects
with androgenetic alopecia using CG210 alone.
In various clinical studies, CG210 has demonstrated efficacy, safety and absence of side-effects as well as
a unique and novel mechanism of action.
ABOUT LEGACY HEALTHCARE
Founded in 2005, Legacy Healthcare is an oncology supportive care and dermatology company. It
develops and markets innovative products for hair & scalp disorders, with a special focus on supportive
oncology treatments, in particular chemotherapy-induced alopecia.
Legacy Healthcare aims to become the first company to market a topical product for the prevention and
recovery from chemotherapy-induced alopecia.
In 2012, the company has finalized the development of CG210™, a patented product for male
androgenetic alopecia and female pattern hair loss. At present, the company is engaged in global
partnering and out-licensing activities.
Lorenzo Pellegrini Quarantotti
VP, Business Development & Commercial Operations
Tel.: +41 21 651 90 36
Dr. Ludger Wess, Ines Regina Buth
Tel.: +49 40 88165964 or +49 30 2363 2768